Benefits
Digestive comfort in adults with mild GI symptoms
In a 6-week pilot sponsored by Kemin, 20 adults with mild digestive symptoms took 600 mg daily. Kemin reports a 39% improvement in symptom severity on the Gastrointestinal Symptom Rating Scale, where indigestion was the main outcome, and no serious adverse events. There was no placebo group and the data are not peer-reviewed, so natural improvement or a placebo response cannot be ruled out.
Digestion-related quality of life
The same uncontrolled pilot tracked digestion-related quality of life with the DQLQ questionnaire, and Kemin reports a 41% decrease in DQLQ scores from baseline. Without a comparison group, this change cannot be credited to ButiShield with confidence.
Abdominal comfort with encapsulated sodium butyrate
In a 12-week double-blind trial of 52 adults with type 2 diabetes and IBS-type symptoms, 1.5 g a day of microencapsulated sodium butyrate resolved abdominal pain in 54% of those analysed versus 5% on placebo, and bloating in 65% versus 5%. The symptom questionnaire was not a validated tool, and the product was sodium butyrate, not ButiShield.
Fuel for the cells lining the colon
Butyrate made by gut bacteria from fiber is a key energy source for colonocytes, the cells that line the colon, and animal research links adequate butyrate to normal colonocyte function. This is a general property of butyrate; it was not measured as an outcome for ButiShield.
Gut barrier support (cell-model mechanism)
In a lab model of human intestinal cells, butyrate sped up assembly of the tight junctions that seal the gut lining, through activation of the enzyme AMPK. This is laboratory evidence about the butyrate molecule. The ButiShield pilot listed gut permeability markers as outcomes, but Kemin has not reported those results.
Gut bacteria that produce short-chain fatty acids
In a placebo-controlled pilot in people with inflammatory bowel disease, 2 months of microencapsulated sodium butyrate added to usual care increased bacteria able to produce short-chain fatty acids. This used a different butyrate salt in a different population; ButiShield's effect on gut bacteria has not been reported.
Mechanism of action
Energy source for colonocytes
Butyrate is a key fuel for colonocytes, the cells lining the colon. In animal models, keeping butyrate levels adequate supports colonocyte function and the gut barrier, which is the basis for interest in supplemental butyrate.
Tight junction assembly
Tight junctions seal neighboring intestinal cells together. In Caco-2 intestinal cell monolayers, butyrate activated the energy-sensing enzyme AMPK and sped up tight junction assembly, raising electrical resistance across the cell layer; blocking AMPK removed the effect.
Gene-expression and receptor signaling
Butyrate inhibits histone deacetylase (HDAC) enzymes, which changes how genes are expressed, and it also signals through three G-protein coupled receptors on cells. These signaling roles are described mainly from laboratory and animal research.
Two-way link with gut bacteria
Gut bacteria produce butyrate by fermenting fiber, and butyrate levels in turn influence both host and microbial functions. In one controlled study, microencapsulated sodium butyrate increased short-chain-fatty-acid-producing bacteria; whether ButiShield does the same has not been tested.
MicroPEARLS spray-freezing encapsulation
Kemin's spray-freezing process forms microparticles that the company says release butyric acid gradually along the digestive tract and mask its odor. Independent human data on where ButiShield releases butyrate in the gut have not been published.
Clinical trials
Single-arm, unmasked 6-week pilot sponsored by Kemin Foods, reviewed by Sterling Institutional Review Board and run by BioFortis; registered as NCT06397482 with no results posted on ClinicalTrials.gov. Primary outcome: change in indigestion symptom severity on the Gastrointestinal Symptom Rating Scale. Results are available only as sponsor-provided industry content, not a peer-reviewed paper (Kemin Health and Human Nutrition, undated, NutraIngredients Scientific Frontiers).
20 adults aged 18 to 60 (75% female) with at least mild indigestion symptoms who ate a typical Western diet; 600 mg ButiShield once daily for 6 weeks, with no placebo group.
Kemin reports that indigestion and all other GI symptom scores except diarrhea improved by day 8 and stayed improved through week 6 (P<0.001), a 39% reduction in symptom severity, plus a 41% decrease in DQLQ scores and no serious adverse events. Results for the gut permeability markers were not reported. Without a placebo group or peer review, these findings are preliminary.
Prospective, randomized, double-blind, placebo-controlled 12-week pilot, retrospectively registered as ISRCTN10844715. Primary outcome: abdominal pain on a study-specific, non-validated questionnaire. Tests sodium butyrate, not ButiShield (Panufnik et al. 2026, Scientific Reports).
52 adults with type 2 diabetes who met Rome IV criteria for IBS (29 sodium butyrate, 23 placebo); 1.5 g/day microencapsulated sodium butyrate.
Abdominal pain, the primary outcome, resolved in 53.8% of the butyrate group versus 4.8% on placebo (p=0.001), and bloating in 65.4% versus 4.8% (p<0.001); diarrhea and constipation also resolved more often with butyrate. Positive lactulose hydrogen breath tests fell from 76.9% to 26.9% with butyrate, with no significant change on placebo. Every butyrate patient had bloating at baseline versus 82.6% on placebo, and 47 of 52 were analysed.
Double-blind, placebo-controlled pilot of 2 months of microencapsulated sodium butyrate added to conventional therapy, with gut bacteria assessed by 16S sequencing. Tests sodium butyrate, not ButiShield (Facchin et al. 2020, Neurogastroenterology & Motility).
49 patients with inflammatory bowel disease (19 Crohn's disease, 30 ulcerative colitis), plus 18 healthy volunteers as a reference group.
Sodium butyrate increased short-chain-fatty-acid-producing bacteria (Lachnospiraceae) in ulcerative colitis and butyrate-producing Butyricicoccus in Crohn's disease, and quality of life improved in the ulcerative colitis group. The authors state the clinical impact needs further study.